Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWPS019
- Development stage
- Preclinical
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
01
Overview
DWPS019 is an investigational small molecule therapeutic being developed by Daewoong Pharmaceutical for the treatment of systemic lupus erythematosus (SLE). SLE is a chronic, systemic autoimmune disease characterized by the production of autoantibodies and multi-organ inflammation, which can lead to significant tissue damage. DWPS019 is part of Daewoong's immunology R&D portfolio, which focuses on addressing unmet needs in autoimmune and inflammatory disorders. As of the current pipeline disclosures, the specific molecular target and mechanism of action for DWPS019 have not been publicly identified, and the asset is in the early stages of development.
Beyond the preview
Go deeper on DWPS019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWPS019.